Tradipitant is under clinical development by Vanda Pharmaceuticals and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Tradipitant’s likelihood of approval (LoA) and phase transition for Gastroparesis took place on 08 Dec 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Tradipitant Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Tradipitant overview

Tradipitant (VLY-686, LY-686017) is under development for the treatment of  gastroparesis, functional dyspepsia and motion sickness. It is administered through oral route as a capsule. The drug candidate is a new chemical entity that targets neurokinin-1 (NK-1) receptor. LY-686017 was also under development for the treatment of anxiety, social phobia, craving during anxiety associated alcohol dependence and treatment-resistant pruritus in atopic dermatitis.

It was under development for the treatment of pneumonia associated with Coronavirus disease 2019 (COVID-19).

Vanda Pharmaceuticals overview

Vanda Pharmaceuticals (Vanda) a biopharmaceutical company that develops and commercializes novel therapies for the treatment of central nervous system disorders. The company’s products include Hetlioz, a melatonin receptor agonist for the treatment of non-24-hour sleep-wake disorder; and Fanapt, a typical antipsychotic for the treatment of schizophrenia in adults. Its major pipeline products include Tradipitant (VLY-686), VTR-297, VQW-765, CFTR and portfolio of cystic fibrosis transmembrane conductance regulator inhibitors and activators. Vanda is headquartered in Washington, Washington DC, the US.

Quick View Tradipitant LOA Data

Report Segments
  • Innovator
Drug Name
  • Tradipitant
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Dermatology
  • Gastrointestinal
  • Infectious Disease
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.